Comparison · NCT03137173-e7ecaf44
Ceftobiprole Medocaril vs Vancomycin+Aztreonam: Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftobiprole Medocaril vs Vancomycin+Aztreonam: Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population. Trial comparisons, record NCT03137173-e7ecaf44. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03137173-e7ecaf44
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.979 | 0.955 | 0.99 | wilson | |
| Risk in group 2 | 0.952 | 0.921 | 0.971 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0266 | -0.00431 | 0.0595 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.997 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 2.32 | 0.878 | 6.12 | log | |
| Number needed to treat, for one more participant with the outcome on Ceftobiprole Medocaril than on Vancomycin+Aztreonam | 37.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftobiprole Medocaril | Patients treated with ceftobiprole medocaril 500 mg every 8 Hours (with dose adjustment for renal impairment). Duration of infusion: 2 hours. | 277 | 283 | OG000 |
| Group 2 | Vancomycin+Aztreonam | Vancomycin 1000 mg (or 15 mg/kg) every 12 hours plus aztreonam 1000 mg every 12 hours (both with dose adjustment for renal impairment). Vancomycin dose adjustment for obese and hypermetabolic patients was according to local standard of care. The requirement for aztreonam therapy was to be reassessed at the 72-hour study visit. Duration of vancomycin infusion: 2 hours; duration of aztreonam infusion: 0.5 hours. | 279 | 293 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population
- Description
- Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population
- Time frame
- 15-22 days after randomization
- Population
- CE population
Source ClinicalTrials.gov
Trial
- Title
- Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
- NCT number
- NCT03137173
- Phases
- PHASE3
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- ceftobiprole medocaril, vancomycin+aztreonam
- Lead sponsor
- Basilea Pharmaceutica
- Results first posted
- 2020-05-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03137173?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03137173-e7ecaf44